Clinical-stage biopharmaceutical company developing therapies for patients with eye diseases.
Tarsus Pharmaceuticals, Inc., headquartered in Irvine, California, is a clinical-stage biopharmaceutical company dedicated to advancing novel therapeutic candidates for various ophthalmic conditions. The company's primary focus lies in developing and commercializing innovative treatments that address unmet medical needs in eye care.
At the forefront of its pipeline is TP-03, a groundbreaking therapeutic currently in Phase III clinical trials. TP-03 aims to effectively treat blepharitis caused by Demodex mite infestation, as well as meibomian gland disease, offering promising solutions for these prevalent eye conditions.
Additionally, Tarsus Pharmaceuticals is advancing TP-04, designed to address rosacea, and TP-05, targeting Lyme disease prophylaxis and community malaria reduction. The company's commitment extends beyond ophthalmology with the development of lotilaner, intended to treat diseases across diverse therapeutic categories in human medicine, including dermatological conditions.
Established in 2016, Tarsus Pharmaceuticals has rapidly emerged as a leader in the biopharmaceutical industry, driven by its dedication to scientific innovation and patient-centric solutions. With a robust pipeline and strategic focus on addressing critical medical challenges, the company continues to pave the way for advancements in ophthalmic and broader therapeutic treatments worldwide.